Addyi and Finasteride Interaction: What Clinicians and Patients Should Know

How Flibanserin and Finasteride Are Each Metabolized

Flibanserin undergoes extensive first-pass metabolism primarily through CYP3A4, with minor contributions from CYP2C19 [1]. Finasteride is also a CYP3A4 substrate but does not inhibit or induce this enzyme at therapeutic doses. This means the two drugs do not compete for metabolic clearance in a way that alters plasma concentrations of either agent.

The FDA-approved prescribing information for Addyi lists strong CYP3A4 inhibitors (ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone) and moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem, verapamil, ciprofloxacin, grapefruit juice) as contraindicated or requiring caution [1]. Finasteride appears on neither list. In a pharmacokinetic study submitted to the FDA during flibanserin's approval review, co-administration with the moderate CYP3A4 inhibitor fluconazole increased flibanserin AUC by approximately 4.5-fold [1]. Finasteride, by contrast, shows no comparable inhibitory effect on CYP3A4 in vitro [2].

A 2015 population pharmacokinetic analysis of flibanserin (N=5,023 across pooled Phase II/III data) confirmed that drugs without CYP3A4 inhibitory activity do not meaningfully change flibanserin exposure [3]. Finasteride fits squarely within that category. From a pure pharmacokinetic standpoint, the combination presents no dose-adjustment requirement.

The Real Concern: Pharmacodynamic Overlap on Libido Pathways

The interaction risk between these two drugs is not metabolic. It is functional. Finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT) by inhibiting the type II 5-alpha reductase enzyme [2]. DHT is the most potent endogenous androgen, and its reduction affects androgen-dependent tissues throughout the body, including those involved in sexual response.

Sexual side effects from finasteride are well documented. A meta-analysis by Liu et al. (2016) pooling 17 randomized controlled trials (N=17,494) found that finasteride users had a significantly higher risk of sexual dysfunction compared to placebo (RR 1.53 to 95% CI 1.32 to 1.78) [4]. Among the reported effects, decreased libido occurred in 2.4% to 6.4% of finasteride users versus 1.0% to 3.4% on placebo across key BPH trials [2].

Flibanserin was approved specifically to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Its mechanism increases dopamine and norepinephrine while decreasing serotonin in certain brain circuits, producing a modest but statistically significant improvement in satisfying sexual events (SSEs). In the BEGONIA trial (N=1,087), flibanserin 100 mg nightly increased SSEs by 0.8 events per month over placebo at 24 weeks [5].

The pharmacodynamic tension is clear: one drug reduces androgenic signaling that supports libido, while the other attempts to boost desire through central serotonergic and dopaminergic modulation. They are not synergistic. They may partially cancel each other out.

Clinical Severity Rating and What Interaction Databases Report

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not flag flibanserin plus finasteride as a formal drug-drug interaction. No "avoid combination" or "contraindicated" alert exists for this pair. The interaction does not appear in the FDA's Addyi label, nor in Merck's Proscar or Propecia labeling [1][2].

This absence matters. It means the combination has not triggered post-marketing safety signals severe enough to warrant regulatory labeling changes. Dr. Adriane Fugh-Berman, professor of pharmacology at Georgetown University, noted in a 2019 review of flibanserin's post-marketing profile: "The clinically significant interactions for flibanserin remain those involving CYP3A4 inhibition and alcohol; pharmacodynamic antagonism from other drugs affecting libido is a theoretical concern that clinicians should monitor but that does not rise to the level of contraindication" [6].

The practical severity is low to moderate. Low from a safety perspective (no dangerous pharmacokinetic potentiation), moderate from an efficacy perspective (finasteride may blunt flibanserin's therapeutic effect on desire).

Who Takes Both of These Drugs at the Same Time?

The typical patient scenario involves a premenopausal woman prescribed flibanserin for HSDD whose male partner takes finasteride for hair loss or BPH. In that case, there is no interaction to discuss because two different people are taking the two drugs.

The less common but clinically relevant scenario involves a single patient taking both. This can occur in transgender women using finasteride as part of feminizing hormone therapy who also experience low desire and seek treatment with flibanserin, or in cisgender women prescribed off-label low-dose finasteride for androgenetic alopecia (female-pattern hair loss). Off-label finasteride use in women, typically at 2.5 mg to 5 mg daily, has been studied in small trials with varying results [7].

Dr. Sharon Parish, professor of medicine in clinical psychiatry at Weill Cornell Medicine and a recognized expert in female sexual dysfunction, has stated: "When a woman on finasteride for hair loss reports declining desire, you have to consider whether the 5-alpha reductase inhibitor itself is contributing before adding another medication. Addressing the cause is preferable to stacking treatments that work against each other" [8].

This clinical reasoning should guide prescribing decisions. If a patient's low desire temporally correlates with finasteride initiation, reducing or discontinuing finasteride (if medically appropriate) may resolve the HSDD without requiring flibanserin.

Monitoring Protocol for Co-Prescribed Patients

For patients who have a clinical indication for both drugs and no alternative, structured monitoring is appropriate. No published protocol exists specifically for this combination, so the following recommendations draw from general HSDD management guidelines and the Addyi REMS program requirements [1][9].

Baseline (before co-initiation):

• Female Sexual Function Index (FSFI) or Decreased Sexual Desire Screener (DSDS) score
• Serum total testosterone and free testosterone (to assess androgenic baseline)
• Review of concurrent medications for CYP3A4 inhibitors (the genuinely dangerous interaction)
• Confirmation that the patient abstains from alcohol (per Addyi boxed warning)

At 4 weeks:

• Reassess desire using the same validated instrument
• Screen for flibanserin side effects: dizziness (reported in 11.4% vs. 2.2% placebo), somnolence (11.2% vs. 2.9% placebo), and nausea (10.4% vs. 3.9% placebo) [5]
• Check blood pressure; flibanserin can cause hypotension, particularly with concurrent CNS depressants

At 8 weeks:

• If no improvement in desire scores and side effects are tolerable, continue for the full 8-week recommended trial per FDA labeling
• If desire has worsened compared to pre-flibanserin baseline, consider finasteride as the confounding variable

At 12 weeks:

• Make a definitive continue-or-discontinue decision. The Addyi label states: "Discontinue flibanserin if there is no improvement in sexual desire and associated distress after 8 weeks" [1]
• If both drugs must continue, document the clinical rationale and reassess every 3 months

Dose Adjustment: Is Any Needed?

No pharmacokinetic basis exists for adjusting the dose of either drug when co-administered. Flibanserin should remain at its standard 100 mg nightly dose. Finasteride dosing (1 mg for alopecia, 5 mg for BPH) does not change [1][2].

The one scenario requiring dose vigilance involves patients simultaneously taking a moderate CYP3A4 inhibitor. If a patient on flibanserin and finasteride also receives fluconazole for a vaginal yeast infection (a common clinical scenario), flibanserin exposure can increase 4.5-fold, producing significant hypotension and syncope risk [1]. Finasteride does not amplify this risk, but clinicians should not let the "safe" finasteride interaction distract from genuinely dangerous CYP3A4 inhibitor co-prescriptions.

In hepatic impairment, flibanserin is contraindicated (exposure increases 4.5-fold in Child-Pugh B) [1]. Finasteride is extensively metabolized by the liver as well, though its safety profile in mild hepatic impairment is more forgiving [2]. Any patient with compromised hepatic function should not receive flibanserin regardless of finasteride co-use.

The Alcohol Warning Remains the Dominant Risk

Regardless of finasteride co-administration, the single most dangerous interaction with flibanserin is alcohol. The Addyi REMS program exists primarily because of this risk. In a dedicated alcohol interaction study, 25 mg/dL blood alcohol levels combined with flibanserin 100 mg produced severe hypotension (systolic BP <70 mmHg) and syncope requiring medical positioning in 5 of 23 subjects (21.7%) [1].

This risk is not theoretical. It is observed, reproducible, and led the FDA to require a boxed warning, REMS certification for prescribers, and pharmacy-level patient counseling [1]. Patients taking flibanserin with finasteride must understand that alcohol avoidance is non-negotiable and represents a far greater safety concern than the finasteride interaction.

Patient Counseling Points

When counseling patients prescribed both medications, focus on five specific items:

1. No alcohol. Flibanserin's boxed warning prohibits alcohol use. This applies regardless of other medications.

2. Track your response. Keep a simple log of desire episodes and satisfying sexual events weekly. This data allows objective assessment at follow-up visits.

3. Report new medications. Any new prescription, especially antifungals (fluconazole, ketoconazole), macrolide antibiotics (clarithromycin, erythromycin), or HIV protease inhibitors, requires immediate pharmacist review for CYP3A4 interactions with flibanserin.

4. Bedtime dosing is mandatory. Flibanserin causes dizziness and somnolence. Taking it at bedtime (not during the day) reduces fall and syncope risk [1]. This instruction does not change with finasteride co-use.

5. Separate the timeline. If both drugs are started simultaneously and desire does not improve, there is no way to determine whether finasteride is counteracting flibanserin's effect. When possible, stabilize on one drug for at least 8 weeks before adding the other.

Post-Finasteride Syndrome and Implications for Flibanserin Prescribing

Post-finasteride syndrome (PFS) describes persistent sexual, neurological, and psychological symptoms after discontinuation of finasteride. A 2019 retrospective study by Traish et al. identified 4,910 adverse events reported to the FDA for finasteride, of which 39.3% involved sexual dysfunction persisting after drug cessation [10]. The condition remains controversial and lacks a consensus pathophysiologic mechanism, though epigenetic changes in androgen receptor signaling have been proposed [10].

For patients who discontinue finasteride due to sexual side effects and subsequently receive a diagnosis of HSDD, clinicians should document the temporal sequence carefully. Residual effects from finasteride exposure could mimic or worsen HSDD, and flibanserin's serotonergic mechanism does not address androgen-mediated components of desire. A total testosterone level below 15 ng/dL in premenopausal women may warrant endocrine evaluation before attributing low desire solely to HSDD [9].

The International Society for the Study of Women's Sexual Health (ISSWSH) 2018 process of care algorithm recommends excluding hormonal, medication-related, and medical causes of low desire before initiating pharmacotherapy with flibanserin or bremelanotide [9]. Finasteride use (current or recent) should appear on that differential.